Medicine and Dentistry
Abdominal Tumor
10%
Adverse Outcome
20%
Alendronic Acid
10%
Androgen Therapy
33%
Anosmia
16%
Asymptomatic Disease
10%
Bisphosphonate
30%
Bone Density
20%
Bone Turnover
10%
Cardiovascular Disease
10%
Catecholamine
39%
Chorionic Gonadotropin
50%
Cinacalcet
30%
Clodronic Acid
10%
Combination Therapy
10%
Congenital Disorder
16%
Denosumab
34%
Diseases
10%
Fetus Death
10%
Genetic Predisposition
10%
Genetic Screening
16%
Gonadotropin
33%
Gonadotropin-Releasing Hormone
33%
Heterozygosity
16%
Hypogonadism
16%
Hypogonadotropic Hypogonadism
50%
Inhibin B
33%
Isotopes of Calcium
50%
Kallmann Syndrome
50%
Logistic Regression Analysis
10%
Maternal Death
10%
Maturation
16%
Meta-Analysis
10%
Meta-Regression
10%
Neoplasm
13%
Odanacatib
25%
Odds Ratio
10%
Pamidronic Acid
10%
Paraganglioma
60%
Parathyroid Hormone
10%
Pheochromocytoma
100%
Premenopause
10%
Prevalence
9%
Primary Hyperparathyroidism
50%
Retrospective Cohort Study
54%
Retrospective Study
20%
Symptom
13%
Systematic Review
100%
Virilization
16%
Keyphrases
Abdominal Tumor
10%
Adrenergic Blockade
30%
Adverse Pregnancy
10%
Anosmia
16%
Asymptomatic Diseases
10%
Blosozumab
16%
Calcimimetics
10%
Case Detection
10%
Catecholamine Excess
30%
Cinacalcet
30%
Commercial Relations
16%
Diphosphate
16%
Email Service
16%
Etelcalcetide
16%
Fetal Death
10%
GnRH Deficiency
33%
Inhibin B
33%
Ipriflavone
16%
Kallmann Syndrome
50%
LESS Surgery
10%
Literature Search Strategy
16%
Odanacatib
16%
Ovarian Maturation
16%
Paraganglioma
10%
Pelvic Tumor
10%
Pregnancy Registry
20%
PROKR2
16%
Prolia
16%
Puberty Induction
50%
Romosozumab
16%
Surgery in Pregnancy
10%
Sympathetic Paraganglioma
50%
Testicular Volume
33%
Testosterone Replacement
33%
Trabecular Bone Score
50%
Virilization
16%
Xgeva
16%
Nursing and Health Professions
Asymptomatic Disease
10%
Blosozumab
15%
Body Mass
27%
Cinacalcet
30%
Clodronic Acid
10%
Cohort Analysis
50%
Cross-Sectional Study
11%
Denosumab
34%
Dual Energy X Ray Absorptiometry
16%
Etelcalcetide
45%
Fragility Fracture
5%
Ipriflavone
5%
Isoflavone Derivative
5%
Medical History
5%
Odanacatib
25%
Outpatient
50%
Outpatient Department
5%
Pamidronic Acid
10%
Parathyroid Hormone
10%
Predictive Value
11%
Primary Hyperparathyroidism
50%
Romosozumab
25%
University Hospital
5%
